Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Paclitaxel + carboplatin is a combination chemotherapy regimen used to treat various cancers, including ovarian, endometrial, cervical, non-small cell lung cancer, and others. Paclitaxel is an anti-microtubule inhibitor derived from the bark of Pacific Yew trees; it disrupts microtubule function and arrests cells in the G2/M phase of the cell cycle, preventing cancer cell division. Carboplatin is an alkylating agent that causes DNA crosslinking and damage, leading to apoptosis in rapidly dividing cells. The combination works synergistically—paclitaxel-induced cell cycle arrest enhances the formation of carboplatin-DNA adducts by inhibiting DNA repair mechanisms[5][6][8]. Both drugs are administered intravenously in cycles.
- Brand names
- CarboTaxol
- Other names
- CARBOPLATIN-TAXOLcarboplatin/paclitaxel regimen
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin.